logo-loader
viewDyadic International Inc

Dyadic International CEO reflects on 2018 accomplishments and reveals year-end earnings

Dyadic International Inc (OTCQX:DYAI) CEO Mark Emalfarb reflects on the company's achievements for 2018, telling Proactive Investors that among its list of accomplishments, the Florida-based biotech company has signed new proof-of-concept research collaborations with two of the "top 25 pharmaceutical companies."

Emalfarb added the company has enough cash on hand to carry the company's list of ongoing studies through the next four to five years.

Quick facts: Dyadic International Inc

Price: 6.08 USD

NASDAQ:DYAI
Market: NASDAQ
Market Cap: $165.46 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Dyadic International Inc named herein, including the promotion by the Company of Dyadic International Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Dyadic touts recent collaborations, 3Q highlights at Jefferies London...

Dyadic International Inc (NASDAQ:DYAI) CEO Mark Emalfarb and CCO Matthew Jones tell Proactive's Andrew Scott the duo are in London for the Jefferies London Healthcare Conference, the biotech's third year attending.  Emalfarb and Jones say the Florida-based biotech is touting its recent...

2 weeks, 5 days ago

2 min read